Olympus Corporation announces that at the Board of Directors Meeting held February 13, 2026, it was tentatively decided to change Chief Financial Officer (CFO). It is scheduled to be decided formally by the Board of Directors in March 2026 and to take effect on April 1, 2026. To further strengthen management structure, the appointment of Chief Financial Officer has been tentatively made based on succession plan. The successor, Michael Parenti, brings extensive leadership experience across a broad range of Finance functions at global MedTech and healthcare companies. In addition to his U.S. based experience, he has served as CFO in Japan and China, where he successfully led Finance organizations in complex, multicultural environments. Leveraging his global perspective and proven leadership, Michael is expected to further enhance the company's financial management capabilities, support disciplined capital allocation, and contribute to sustainable growth and value creation as a Japan-originated global MedTech company. Appoints Michael Parenti as Executive Officer and departure of Tatsuya Izumi as Executive Officer . Michael Parenti: Date of Birth is September 6, 1977; Career summary: January 2001 - Joined Johnson & Johnson at Ethicon Endo-Surgery; May 2006 - Finance Manager, Ethicon Endo-Surgery, Johnson & Johnson; May 2008 - Finance Manager, Depuy Orthopedics, Johnson & Johnson
April 2010 Senior Finance Manager, Depuy Orthopedics, Johnson & Johnson, September 2012 Finance Director, Merger and Acquisitions, Johnson & Johnson, September 2015 Senior Finance Director and CFO, Johnson & Johnson China Ltd. August 2018 Vice President of Finance and CFO, Johnson & Johnson K.K.(Japan), February 2021 Vice President, Group CFO, MedSurg and NeuroTech, Stryker (present), April 2026 Executive Officer, Chief Financial Officer, Olympus Corporation (plan).
Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, scientific and other products. The Company operates through three business segments. The Endoscope segment provides gastrointestinal endoscopes, surgical endoscopes, and medical services. The Therapeutic Equipment segment provides gastrointestinal treatment instruments, urology products, respiratory products, energy devices, otolaryngology products and gynecology products. The Others segment provides biomaterials and orthopedic instruments. The Company is also engaged in the business activities, including holding companies and financial investments related to each business.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
